Olmesartan/Amlodipin 1a Pharma (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olmesartan/Amlodipin 1a Pharma, is a Angiotensin II receptor blocker (ARB) presented as a fixed‑dose oral tablet for oral use. It is combined with amlodipine, a calcium‑channel blocker, to treat hypertension in adult patients. GNH USA supplies Olmesartan/Amlodipin 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipin acts on the renin‑angiotensin system and vascular smooth muscle to lower blood pressure in hypertensive patients. - Hypertension: provides sustained reduction of systolic and diastolic blood pressure. - Essential hypertension: offers consistent control when monotherapy is insufficient. - Hypertensive patients requiring combination therapy: delivers two complementary mechanisms in a single tablet, improving adherence.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially after standing. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Flushing: transient warmth and reddening of the skin.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Myocardial infarction: chest pain or other signs of heart attack. - Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment.

Patients and prescribers should observe several safety measures before and during treatment. - Blood pressure monitoring: check regularly to ensure therapeutic targets are met. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with existing kidney disease. - Hepatic impairment: use caution and consider dose adjustment in severe liver dysfunction. - Pregnancy: avoid use unless clearly needed; safety data are limited. - Concomitant potassium‑sparing agents: monitor serum potassium to prevent hyperkalaemia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Amlodipin may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: increased risk of hyperkalaemia and renal impairment. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - Cyclosporine: can raise olmesartan plasma concentrations. - Simvastatin: amlodipine raises statin levels, increasing risk of myopathy. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect, watch for hypotension. - Rifampin: induces metabolism, potentially reducing amlodipine exposure. - Digoxin: monitor serum levels as amlodipine may increase concentrations. - Beta‑blockers: may enhance bradycardia; observe heart rate.